📰 **Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent**

Eli Lilly's 2026 is off to a great start, with massive earnings and revenue beats and exciting updates about its latest GLP-1, Foundayo.

🔗 https://www.marketbeat.com/originals/lillys-double-beat-widens-the-glp-1-gapand-a-new-pill-could-make-it-permanent/

#markets #news